Onartuzumab for Gastroesophageal Adenocarcinoma

Manish A Shah, MD, director of gastrointestinal oncology at Weill Cornell Medical College/New York Presbyterian Hospital, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma (GEC).

Clinical Pearls:

• The MET pathway is often overexpressed in gastric cancer. If there is a MET amplification in addition to the overexpression, the cancer can be more aggressive.
• The study found that the addition of onartuzumab to FOLFOX did not improve progression-free survival or overall survival in either an unselected population or in MET-positive patients.
• More research is needed to identify patients that benefit from MET inhibition